4D Molecular Therapeutics (FDMT) Accumulated Depreciation & Amortization: 2019-2025
Historic Accumulated Depreciation & Amortization for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $20.1 million.
- 4D Molecular Therapeutics' Accumulated Depreciation & Amortization rose 29.52% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.1 million, marking a year-over-year increase of 33.30%. This contributed to the annual value of $16.6 million for FY2024, which is 39.00% up from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Accumulated Depreciation & Amortization is $20.1 million, which was up 6.71% from $18.8 million recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Accumulated Depreciation & Amortization peaked at $20.1 million during Q3 2025, and registered a low of $4.2 million during Q1 2021.
- For the 3-year period, 4D Molecular Therapeutics' Accumulated Depreciation & Amortization averaged around $14.3 million, with its median value being $14.3 million (2024).
- Data for 4D Molecular Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY skyrocketed of 61.32% (in 2023) over the last 5 years.
- 4D Molecular Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $5.3 million in 2021, then surged by 45.13% to $7.7 million in 2022, then spiked by 54.40% to $11.9 million in 2023, then skyrocketed by 39.00% to $16.6 million in 2024, then increased by 29.52% to $20.1 million in 2025.
- Its last three reported values are $20.1 million in Q3 2025, $18.8 million for Q2 2025, and $17.6 million during Q1 2025.